Drugs / FL-101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05395260 | Aug → Nov 2022 | infiltrating bladder urothelial carcinoma | Flame Biosciences | Withdrawn | No outcome recorded Stop: Business |
| Phase 11 trial | ||||||
| Phase 1 | NCT04983732 | Sep 2021 → May 2022 | — | Flame Biosciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04758949 | Aug → Dec 2021 | non-small cell lung carcinoma | Flame Biosciences | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FL-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04758949 ↗ |
| Route | Intravenous | “administered intravenously” NCT04758949 ↗ |